EBS (Elsius Bioactive Surface)

The game changer in biocompatiblity coatings!

The main issue limiting ECMO widespread usage, as well as most blood contacting technologies, is the fact that foreign surfaces when in contact with blood trigger a cascade of unintended effects like inflammatory responses, thrombi formation, white cells activation, proteins absorption, etc. that degrade the blood to the point that ultimately it will kill the patient.

To counter those effects doctors take a number of measures which are effective but in the end have their own side effects. The most glaring example is the use of anti coagulation drugs to diminish the thrombi formation risk but that carry the severe side effect of promoting systemic bleeding. Coatings that enhance the biocomaptibility of materials are another effective way to address those problems but so far the resuts have been mixed.

EBS is part of this last set of solutions and the results so far have been so good that not only it could make the usage of ECMO mainstream but it could transform the way we look at blood contacting surfaces altogether.

EBS has been developed in conjuction with Ension Inc. in Pittsburgh during the best part of ten years. It mimics the way our body contacts blood inside its vessels through a mechanism called the glychocalyx.

EBS has also been tested extensively against competing products already on the market showing a clear advantage.

ECMO is surely one of the most demanding applications in terms of biocompatible surfaces, it has extensive areas, there is substantial flow, different materials are present and there is significant gas exchange between the blood and some surfaces (CO2 taken out of the blood and O2 brought in). a biocomaptible coating to be able to work in conjuction of an ECMO device needs also to be able to whitstand sterilization cycles, transportation and storage of the device for at least two years and shouldn't wash away during extended use.

The tests to allow a coating to be used in a clinical setting are thus very rigorous and extensive and fall under the NAMSA-ISO 10993 standard.

In the end an effective biocompatible coating coupled with an advanced ECMO system, like the EBS coated pCAS system, could result in a significant reduction of adverse effects for the patients, enabling practitioners to reduce support therapies like anticoagulation drugs and consequent hemorragic risk, ultimately resulting in better patients outcomes, less time under therapy, less personell involvment and lower costs for the hospital and society at large.